JP2021533805A5 - - Google Patents
Info
- Publication number
- JP2021533805A5 JP2021533805A5 JP2021510015A JP2021510015A JP2021533805A5 JP 2021533805 A5 JP2021533805 A5 JP 2021533805A5 JP 2021510015 A JP2021510015 A JP 2021510015A JP 2021510015 A JP2021510015 A JP 2021510015A JP 2021533805 A5 JP2021533805 A5 JP 2021533805A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- cpg
- sequence
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024060919A JP7874125B2 (ja) | 2018-08-24 | 2024-04-04 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722547P | 2018-08-24 | 2018-08-24 | |
| US62/722,547 | 2018-08-24 | ||
| US201862725096P | 2018-08-30 | 2018-08-30 | |
| US62/725,096 | 2018-08-30 | ||
| US201862784116P | 2018-12-21 | 2018-12-21 | |
| US62/784,116 | 2018-12-21 | ||
| PCT/US2019/048032 WO2020041773A1 (en) | 2018-08-24 | 2019-08-23 | Optimized promoter sequences, intron-free expression constructs and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060919A Division JP7874125B2 (ja) | 2018-08-24 | 2024-04-04 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533805A JP2021533805A (ja) | 2021-12-09 |
| JP2021533805A5 true JP2021533805A5 (enExample) | 2022-04-26 |
Family
ID=69591143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510015A Pending JP2021533805A (ja) | 2018-08-24 | 2019-08-23 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
| JP2024060919A Active JP7874125B2 (ja) | 2018-08-24 | 2024-04-04 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060919A Active JP7874125B2 (ja) | 2018-08-24 | 2024-04-04 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12290574B2 (enExample) |
| EP (1) | EP3840775A4 (enExample) |
| JP (2) | JP2021533805A (enExample) |
| CN (1) | CN113226352B (enExample) |
| AU (2) | AU2019325688B2 (enExample) |
| BR (1) | BR112021003399A2 (enExample) |
| CA (1) | CA3111047A1 (enExample) |
| MX (1) | MX2021002198A (enExample) |
| TW (1) | TW202012425A (enExample) |
| WO (1) | WO2020041773A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| EP4333886A4 (en) * | 2021-05-07 | 2025-11-12 | Generation Bio Co | NON-VIRAL DNA VECTORS FOR VACCINE ADMINISTRATION |
| WO2022236016A1 (en) * | 2021-05-07 | 2022-11-10 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| AU2023261338A1 (en) * | 2022-04-28 | 2024-11-21 | Joint Stock Company "Biocad" | Codon-optimized nucleic acid encoding the fviii-bdd |
| CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
| EP4598590A4 (en) * | 2022-10-08 | 2026-05-27 | Lingyi Biotech Co Ltd | CONSTRUCTION TO IMPROVE GENE EXPRESSION |
| WO2025264490A1 (en) * | 2024-06-17 | 2025-12-26 | Spark Therapeutics, Inc. | Dna promoters |
| CN119242712A (zh) * | 2024-09-27 | 2025-01-03 | 南京师范大学 | 特异性靶向骨骼肌细胞的携带miRNA-486基因的腺相关病毒载体、药物组合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
| BRPI0515819A (pt) * | 2004-12-01 | 2008-08-05 | Genzyme Corp | métodos para o fornecimento direcionado de material genético ao fìgado |
| US8008468B2 (en) * | 2005-02-16 | 2011-08-30 | Benitec, Inc. | RNAi expression constructs with liver-specific enhancer/promoter |
| WO2011109380A1 (en) | 2010-03-01 | 2011-09-09 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the hcv genome |
| US20140271550A1 (en) * | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
| JP6646282B2 (ja) * | 2014-04-24 | 2020-02-14 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 多発性硬化症のためのａａｖ系遺伝子療法 |
| KR20180014051A (ko) * | 2015-05-28 | 2018-02-07 | 코넬 유니버시티 | 혈관 부종 치료제로서의 아데노-관련 바이러스 매개 c1e1의 전달 |
| EP4378487A3 (en) | 2015-06-23 | 2024-09-04 | The Children's Hospital of Philadelphia | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |
| JP2018535929A (ja) * | 2015-09-24 | 2018-12-06 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
| US10143760B2 (en) * | 2015-10-28 | 2018-12-04 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| EP3293260A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293203A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| KR102617502B1 (ko) | 2016-09-12 | 2023-12-26 | 제네똥 | 산-알파 글루코시다제 변이체 및 이의 용도 |
| CA3086942A1 (en) | 2018-02-07 | 2019-08-15 | Genethon | Hybrid regulatory elements |
| BR112020015488A2 (pt) | 2018-02-08 | 2020-12-08 | Sangamo Therapeutics, Inc. | Nucleases alvo-específicas modificadas |
| SG11202011191WA (en) | 2018-05-16 | 2020-12-30 | Spark Therapeutics Inc | Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same |
| BR112021001498A2 (pt) | 2018-07-27 | 2021-04-27 | Regenxbio Inc. | vírus adeno-associado recombinante (raav), composição farmacêutica, polinucleotídeo, plasmídeo de raav, célula ex vivo, método de produção de um raav e métodos para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo iva (mps iva) |
| CN113795575A (zh) | 2019-02-04 | 2021-12-14 | 自由行疗法有限公司 | 多核苷酸 |
| CA3106693A1 (en) | 2019-02-06 | 2020-08-13 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type i |
| EP3956354A1 (en) | 2019-04-19 | 2022-02-23 | Genethon | Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases |
| US20220195462A1 (en) | 2019-04-24 | 2022-06-23 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| EP4004214A1 (en) | 2019-07-26 | 2022-06-01 | RegenxBio Inc. | Engineered nucleic acid regulatory element and methods of uses thereof |
| US12662512B2 (en) | 2019-10-22 | 2026-06-23 | Genethon | Chimeric polypeptides and uses thereof |
| WO2021078834A1 (en) | 2019-10-22 | 2021-04-29 | Genethon | Chimeric acid-alpha glucosidase polypeptides and uses thereof |
| WO2021087366A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Compositions and methods for genome engineering |
| WO2021084276A2 (en) | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Factor viii construct |
| EP3913060A1 (en) | 2020-05-22 | 2021-11-24 | Genethon | Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy |
| GB202009741D0 (en) | 2020-06-25 | 2020-08-12 | Freeline Therapeutics Ltd | Polynucleotide |
| WO2022182986A1 (en) | 2021-02-26 | 2022-09-01 | Logicbio Therapeutics, Inc. | Manufacturing and use of recombinant aav vectors |
-
2019
- 2019-08-23 CN CN201980070435.4A patent/CN113226352B/zh active Active
- 2019-08-23 WO PCT/US2019/048032 patent/WO2020041773A1/en not_active Ceased
- 2019-08-23 AU AU2019325688A patent/AU2019325688B2/en active Active
- 2019-08-23 MX MX2021002198A patent/MX2021002198A/es unknown
- 2019-08-23 JP JP2021510015A patent/JP2021533805A/ja active Pending
- 2019-08-23 US US17/250,712 patent/US12290574B2/en active Active
- 2019-08-23 EP EP19852321.9A patent/EP3840775A4/en active Pending
- 2019-08-23 BR BR112021003399-8A patent/BR112021003399A2/pt unknown
- 2019-08-23 CA CA3111047A patent/CA3111047A1/en active Pending
- 2019-08-26 TW TW108130505A patent/TW202012425A/zh unknown
-
2024
- 2024-04-04 JP JP2024060919A patent/JP7874125B2/ja active Active
-
2025
- 2025-06-04 AU AU2025204161A patent/AU2025204161A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024009857A5 (enExample) | ||
| CN111902539B (zh) | 杂合调控元件 | |
| EP3313991B1 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| JP7541027B2 (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| JP2022508182A5 (enExample) | ||
| TW201840850A (zh) | 腺相關病毒載體遞送肌肉特異性微小肌縮蛋白以治療肌肉萎縮症 | |
| JP7430898B2 (ja) | 多発性硬化症のためのａａｖ系遺伝子療法 | |
| JP2020533276A5 (enExample) | ||
| JP2022523679A5 (enExample) | ||
| JP7702949B2 (ja) | ヒトｍｅｃｐ２遺伝子を発現するように設計されたトランスジーンカセット | |
| US20020076754A1 (en) | Overcoming AAV vector size limitation through viral DNA hetero-dimerization | |
| JP2022551744A5 (enExample) | ||
| IL283475B1 (en) | Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema | |
| JP2021520811A5 (enExample) | ||
| JP2022536338A (ja) | Ａｒｓａ遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法 | |
| CN117897492A (zh) | 用于肌肉和cns中的基因表达的杂合启动子 | |
| CN113891712A (zh) | 用于晚期婴儿神经元蜡样脂褐质沉积症2型的aav载体治疗方法 | |
| WO2021078834A1 (en) | Chimeric acid-alpha glucosidase polypeptides and uses thereof | |
| JP2022514271A5 (enExample) | ||
| JP7826334B2 (ja) | 髄腔内送達によってピット・ホプキンス症候群を治療するためのメチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルス | |
| TH2201002179A (th) | แคสเสตการถ่ายโอน aav | |
| HK40115222A (en) | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy | |
| HK40126715A (en) | Adeno-associated virus vector delivery of muscle-specific micro-dystrophin to treat muscular dystrophy | |
| JP2025534651A (ja) | 呼吸困難を伴う脊髄性筋萎縮１型（ｓｍａｒｄ１）及びシャルコー・マリー・トゥース２ｓ型（ｃｍｔ２ｓ）を治療するためのアデノ随伴ウイルス送達 | |
| AU2023215308A1 (en) | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia |